Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance

Parkinson's disease is a common, progressive neurodegenerative disorder, affecting 3% of those older than 75 years of age. Clinically, Parkinson's disease (PD) is associated with resting tremor, postural instability, rigidity, bradykinesia, and a good response to levodopa therapy. Over the last 15 years, numerous studies have confirmed that genetic factors contribute to the complex pathogenesis of PD. Highly penetrant mutations producing rare, monogenic forms of the disease have been discovered in singular genes such as SNCA, Parkin, DJ‐1, PINK 1, LRRK2, and VPS35. Unique variants with incomplete penetrance in LRRK2 and GBA have been shown to be strong risk factors for PD in certain populations. Additionally, over 20 common variants with small effect sizes are now recognized to modulate the risk for PD. Investigating Mendelian forms of PD has provided precious insight into the pathophysiology that underlies the more common idiopathic form of disease; however, no treatment methodologies have developed. Furthermore, for identified common risk alleles, the functional basis underlying risk principally remains unknown. The challenge over the next decade will be to strengthen the findings delivered through genetic discovery by assessing the direct, biological consequences of risk variants in tandem with additional high‐content, integrated datasets.

[1]  T. Postmus Genetics of Parkinson's disease , 2018 .

[2]  T. Lim,et al.  F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. , 2015, Human molecular genetics.

[3]  Margaret Sutherland,et al.  Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study , 2015, The Lancet Neurology.

[4]  W. Chung,et al.  Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. , 2015, Brain : a journal of neurology.

[5]  J. Hardy,et al.  Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction , 2015, Brain : a journal of neurology.

[6]  C. Sue,et al.  The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms , 2015, Movement disorders : official journal of the Movement Disorder Society.

[7]  Á. Almeida,et al.  DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1. , 2015, The Biochemical journal.

[8]  S. Scuderi,et al.  Alternative Splicing Generates Different Parkin Protein Isoforms: Evidences in Human, Rat, and Mouse Brain , 2014, BioMed research international.

[9]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[10]  P. A. Lay,et al.  Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes. , 2014, Human molecular genetics.

[11]  Soojay Banerjee,et al.  PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity , 2014, The Journal of cell biology.

[12]  Suneil K. Kalia,et al.  Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease , 2014, Proceedings of the National Academy of Sciences.

[13]  R. Teasdale,et al.  The Vps35 D620N Mutation Linked to Parkinson's Disease Disrupts the Cargo Sorting Function of Retromer , 2014, Traffic.

[14]  P. Giunti,et al.  Inhibition of LRRK2 kinase activity stimulates macroautophagy , 2013, Biochimica et biophysica acta.

[15]  Mark T. W. Ebbert,et al.  Genetics of Alzheimer's Disease , 2013, BioMed research international.

[16]  J. Hardy,et al.  The Parkinson’s disease genes Fbxo7 and Parkin interact to mediate mitophagy , 2013, Nature Neuroscience.

[17]  M. Nalls,et al.  A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. , 2013, JAMA neurology.

[18]  J. Hardy,et al.  Parkin Disease and the Lewy Body Conundrum , 2013, Movement disorders : official journal of the Movement Disorder Society.

[19]  J. Hardy,et al.  Parkin disease: a clinicopathologic entity? , 2013, JAMA neurology.

[20]  Eden R Martin,et al.  Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease , 2013, Neurology.

[21]  J. Zeng,et al.  LRRK2 G2385R and LRRK2 R1628P increase risk of Parkinson's disease in a Han Chinese population from Southern Mainland China. , 2013, Parkinsonism & related disorders.

[22]  A. Consiglio,et al.  Interplay of LRRK2 with chaperone-mediated autophagy , 2013, Nature Neuroscience.

[23]  Ying-Zu Huang,et al.  Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort. , 2013, Parkinsonism & related disorders.

[24]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[25]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[26]  E. Greggio Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. , 2012, Biochemical Society transactions.

[27]  T. Münte,et al.  Frequency of the D620N mutation in VPS35 in Parkinson disease. , 2012, Archives of neurology.

[28]  C. Tanner,et al.  Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. , 2012, Parkinsonism & related disorders.

[29]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[30]  Chunyan Wang,et al.  Leucine‐rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin‐like protein , 2012, Journal of neurochemistry.

[31]  A. Ramírez,et al.  ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome , 2012, Neurobiology of Aging.

[32]  Lun Yang,et al.  Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis. , 2012, Parkinsonism & related disorders.

[33]  J. Novembre,et al.  Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe , 2012, Human Mutation.

[34]  E. Bézard,et al.  Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration , 2012, Proceedings of the National Academy of Sciences.

[35]  S. Klebe,et al.  Identification of VPS35 mutations replicated in French families with Parkinson disease , 2012, Neurology.

[36]  D. Krainc,et al.  Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity , 2012, The Journal of Neuroscience.

[37]  C. Chu,et al.  ATP13A2 regulates mitochondrial bioenergetics through macroautophagy , 2012, Neurobiology of Disease.

[38]  E. Tolosa,et al.  LRRK2 haplotype‐sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation , 2012, Movement disorders : official journal of the Movement Disorder Society.

[39]  A. Grünewald,et al.  Genetics of Parkinson's Disease , 2011, Seminars in neurology.

[40]  John Hardy,et al.  A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. , 2011, Human molecular genetics.

[41]  J. Ioannidis,et al.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study , 2011, The Lancet Neurology.

[42]  A. Brice,et al.  Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. , 2011, Parkinsonism & related disorders.

[43]  Marc N. Offman,et al.  A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. , 2011, American journal of human genetics.

[44]  M. Farrer,et al.  VPS35 mutations in Parkinson disease. , 2011, American journal of human genetics.

[45]  Ying Sun,et al.  Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.

[46]  D. Hernandez,et al.  Genome-wide association study confirms extant PD risk loci among the Dutch , 2011, European Journal of Human Genetics.

[47]  H. Mortiboys,et al.  Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 , 2010, Neurology.

[48]  Alexander Münchau,et al.  Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. , 2010, Archives of neurology.

[49]  Matti Pirinen,et al.  Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21 , 2010, Human molecular genetics.

[50]  J. Nutt,et al.  Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[51]  T. Hashimoto,et al.  Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism , 2010, Neurology.

[52]  K. Lohmann,et al.  Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts , 2010, PloS one.

[53]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[54]  C. Duyckaerts,et al.  Leucine-Rich Repeat Kinase 2 Is Associated With the Endoplasmic Reticulum in Dopaminergic Neurons and Accumulates in the Core of Lewy Bodies in Parkinson Disease , 2010, Journal of neuropathology and experimental neurology.

[55]  J. Nutt,et al.  Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.

[56]  A. Prescott,et al.  14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization , 2010, The Biochemical journal.

[57]  P. Visscher,et al.  Common SNPs explain a large proportion of heritability for human height , 2011 .

[58]  Nilanjan Chatterjee,et al.  Estimation of effect size distribution from genome-wide association studies and implications for future discoveries , 2010, Nature Genetics.

[59]  S. Tiamkao,et al.  Frequencies of LRRK2 variants in Thai patients with Parkinson's disease: evidence for an R1628P founder , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[60]  J. Hay,et al.  α-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREs , 2010, Molecular biology of the cell.

[61]  Marc Cruts,et al.  Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.

[62]  C. Sampaio,et al.  Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. , 2010, Parkinsonism & related disorders.

[63]  J. Jankovic,et al.  Multiple LRRK2 variants modulate risk of Parkinson disease: a chinese multicenter study , 2010, Human mutation.

[64]  Eden R Martin,et al.  Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.

[65]  E. Shin,et al.  The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. , 2010, Parkinsonism & related disorders.

[66]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[67]  Atsushi Tanaka,et al.  PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.

[68]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[69]  M. Cookson,et al.  The R1441C mutation alters the folding properties of the ROC domain of LRRK2. , 2009, Biochimica et biophysica acta.

[70]  Z. Wszolek,et al.  Clinical features of LRRK2 parkinsonism. , 2009, Parkinsonism & related disorders.

[71]  M. Cookson,et al.  The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. , 2009, Biochemical and biophysical research communications.

[72]  M. Farrer,et al.  A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. , 2009, Parkinsonism & related disorders.

[73]  H. Cai,et al.  Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement of Actin Cytoskeleton in Neuronal Morphogenesis , 2009, The Journal of Neuroscience.

[74]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[75]  E. Sidransky,et al.  MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET , 2009, Neurology.

[76]  Yih-Ru Wu,et al.  LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi‐center pooled analysis , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[77]  G. Schellenberg,et al.  LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[78]  M. Ueffing,et al.  The Parkinson disease‐associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro , 2009, Journal of neurochemistry.

[79]  U. Pettersson Faculty Opinions recommendation of Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. , 2009 .

[80]  A. Destée,et al.  Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson’s disease , 2009, Journal of Medical Genetics.

[81]  J. Lucas,et al.  Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options , 2009, European journal of neurology.

[82]  A. Paetau,et al.  Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo , 2009, Molecular Brain.

[83]  S. Lindquist,et al.  α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.

[84]  T. Foroud,et al.  Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset , 2009, Neurology.

[85]  W. Oyen,et al.  FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome , 2009, Neurology.

[86]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[87]  E. Elahi,et al.  R632W mutation in PLA2G6 segregates with dystonia‐parkinsonism in a consanguineous Iranian family , 2009, European journal of neurology.

[88]  H. Karlsson The prevalence of what? , 2009, Nordic journal of psychiatry.

[89]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[90]  T. Ikeuchi,et al.  PROMINENT PSYCHIATRIC SYMPTOMS AND GLUCOSE HYPOMETABOLISM IN A FAMILY WITH A SNCA DUPLICATION , 2008, Neurology.

[91]  A. Brice,et al.  α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.

[92]  Y. Sohn,et al.  Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease , 2008, Neurogenetics.

[93]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[94]  M. Farrer,et al.  Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease , 2008, Annals of neurology.

[95]  D. Hernandez,et al.  Characterization of PLA2G6 as a locus for dystonia‐parkinsonism , 2008, Annals of neurology.

[96]  M. Ronaghi,et al.  Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. , 2008, American journal of human genetics.

[97]  V. Mok,et al.  LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson’s disease compared to late-onset patients , 2008, Journal of Neural Transmission.

[98]  M. Esiri,et al.  LRRK2 is a component of granular alpha‐synuclein pathology in the brainstem of Parkinson's disease , 2008, Neuropathology and applied neurobiology.

[99]  M. Farrer,et al.  Genomic investigation of α‐synuclein multiplication and parkinsonism , 2008, Annals of neurology.

[100]  A. Kakita,et al.  Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. , 2008, Archives of neurology.

[101]  A. Singleton,et al.  Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls , 2008, Human mutation.

[102]  R. Schmidt,et al.  Molecular Pathogenesis of Genetic and Inherited Diseases Disrupted Membrane Homeostasis and Accumulation of Ubiquitinated Proteins in a Mouse Model of Infantile Neuroaxonal Dystrophy Caused by PLA 2 G 6 Mutations , 2010 .

[103]  S. Lindquist,et al.  The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis , 2008, Proceedings of the National Academy of Sciences.

[104]  B. Jeon,et al.  α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.

[105]  Ying Wang,et al.  The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease , 2007 .

[106]  Jian-jun Liu,et al.  Analysis of LRRK2 Gly2385Arg genetic variant in non‐Chinese Asians , 2007, Movement disorders : official journal of the Movement Disorder Society.

[107]  Janel O. Johnson,et al.  Comprehensive Screening of a North American Parkinson’s Disease Cohort for LRRK2 Mutation , 2007, Neurodegenerative Diseases.

[108]  C. Ki,et al.  The Ala53Thr mutation in the α‐synuclein gene in a Korean family with Parkinson disease , 2007 .

[109]  M. Farrer,et al.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication , 2007, Neurology.

[110]  M. Farrer,et al.  Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.

[111]  N. Hattori,et al.  Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population , 2007, Neuroreport.

[112]  F. Brancati,et al.  Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum , 2007, Human mutation.

[113]  A. Dürr,et al.  Deletion of the parkin and PACRG gene promoter in early‐onset parkinsonism , 2007, Human mutation.

[114]  A. Abeliovich,et al.  The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.

[115]  T. Foroud,et al.  Mutations in DJ-1 are rare in familial Parkinson disease , 2006, Neuroscience Letters.

[116]  Sonja W. Scholz,et al.  Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.

[117]  Jan Gründemann,et al.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.

[118]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[119]  Colin A. Johnson,et al.  PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.

[120]  K. Xia,et al.  Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. , 2006, Human molecular genetics.

[121]  A. Brice,et al.  LRRK2, gène majeur de la maladie de Parkinson dans les pays du Maghreb , 2006 .

[122]  A. Dürr,et al.  [LRRK2 is a major gene in North African parkinsonism]. , 2006, Medecine sciences : M/S.

[123]  B. Oostra,et al.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan , 2006, Neurogenetics.

[124]  Mark A. Wilson,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein , 2006 .

[125]  Stéphane Thobois,et al.  Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. , 2006, Brain : a journal of neurology.

[126]  C. Klein,et al.  The genetics of Parkinson disease: implications for neurological care , 2006, Nature Clinical Practice Neurology.

[127]  A. Singleton,et al.  Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease , 2006 .

[128]  P. Pollak,et al.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.

[129]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[130]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[131]  A. Brice Genetics of Parkinson's disease: LRRK2 on the rise. , 2005, Brain : a journal of neurology.

[132]  Mariza de Andrade,et al.  High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.

[133]  M. Farrer,et al.  Lrrk2 pathogenic substitutions in Parkinson's disease , 2005, Neurogenetics.

[134]  M. Farrer,et al.  LRRK2 mutations in Parkinson disease , 2005, Neurology.

[135]  F. Menzies,et al.  Roles of Drosophila DJ-1 in Survival of Dopaminergic Neurons and Oxidative Stress , 2005, Current Biology.

[136]  Patrizia Rizzu,et al.  Drosophila DJ-1 Mutants Are Selectively Sensitive to Environmental Toxins Associated with Parkinson’s Disease , 2005, Current Biology.

[137]  J. Balsinde,et al.  Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. , 2005, Cellular signalling.

[138]  P. Bauer,et al.  PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism , 2005, European Journal of Human Genetics.

[139]  M. Farrer,et al.  The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients , 2005, Neuroscience Letters.

[140]  C. Klein,et al.  Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes , 2005, Neurology.

[141]  N. Hattori,et al.  Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism , 2005, Neurology.

[142]  Steven P Gygi,et al.  The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. , 2005, Human molecular genetics.

[143]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[144]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[145]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[146]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[147]  J. Aharon-Peretz,et al.  Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2004, The New England journal of medicine.

[148]  Thomas Floss,et al.  Sensitivity to Oxidative Stress in DJ-1-Deficient Dopamine Neurons: An ES- Derived Cell Model of Primary Parkinsonism , 2004, PLoS biology.

[149]  A. Abeliovich,et al.  DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.

[150]  K. Marder,et al.  Distribution, type, and origin of Parkin mutations: Review and case studies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[151]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[152]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[153]  A. Singleton,et al.  Parkinson's disease and dementia with Lewy bodies: a difference in dose? , 2004, The Lancet.

[154]  D. Goldstein,et al.  The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism , 2004, Annals of neurology.

[155]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[156]  T. Niki,et al.  Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. , 2004, Biochemical and biophysical research communications.

[157]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[158]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[159]  Tomoya Kinumi,et al.  Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. , 2004, Biochemical and biophysical research communications.

[160]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[161]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[162]  T. Niki,et al.  DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.

[163]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[164]  B. Oostra,et al.  DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism , 2003, Neurological Sciences.

[165]  N. Quinn,et al.  The role of pathogenic DJ‐1 mutations in Parkinson's disease , 2003, Annals of neurology.

[166]  C. Woods,et al.  Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum , 2003, Journal of medical genetics.

[167]  Nicholas W Wood,et al.  Parkin disease: a phenotypic study of a large case series. , 2003, Brain : a journal of neurology.

[168]  R. Schiffmann,et al.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? , 2003, Molecular genetics and metabolism.

[169]  Y. Agid,et al.  Parkin mutations are frequent in patients with isolated early-onset parkinsonism. , 2003, Brain : a journal of neurology.

[170]  L. Seeberger,et al.  Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease , 2003, Neurology.

[171]  N. Hattori,et al.  Genotype–phenotype correlation: Familial Parkinson disease , 2003, Neuropathology : official journal of the Japanese Society of Neuropathology.

[172]  P. Lockhart,et al.  Functional association of the parkin gene promoter with idiopathic Parkinson's disease. , 2002, Human molecular genetics.

[173]  J. Pritchard,et al.  The allelic architecture of human disease genes: common disease-common variant...or not? , 2002, Human molecular genetics.

[174]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[175]  D. Hernandez,et al.  Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.

[176]  E. Lander,et al.  On the allelic spectrum of human disease. , 2001, Trends in genetics : TIG.

[177]  A. Lang,et al.  The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. , 2001, Human molecular genetics.

[178]  D. Krasnewich,et al.  Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. , 2001, Molecular genetics and metabolism.

[179]  M. Polymeropoulos,et al.  Clinical phenotype in patients with α-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[180]  A. Bentivoglio,et al.  Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.

[181]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[182]  N. Quinn,et al.  Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations , 2001, Neurology.

[183]  A. Iwamatsu,et al.  Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat , 2001, Free radical research.

[184]  A. Mitsumoto,et al.  DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin , 2001, Free radical research.

[185]  C. Haft,et al.  Human orthologs of yeast vacuolar protein sorting proteins Vps26, 29, and 35: assembly into multimeric complexes. , 2000, Molecular biology of the cell.

[186]  S. Ha,et al.  Sorting of Yeast Membrane Proteins into an Endosome-to-Golgi Pathway Involves Direct Interaction of Their Cytosolic Domains with Vps35p , 2000, The Journal of cell biology.

[187]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[188]  Bonifati,et al.  Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.

[189]  J. Haines,et al.  The α-synuclein gene is not a major risk factor in familial Parkinson disease , 1999, Neurogenetics.

[190]  M. Polymeropoulos,et al.  Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. , 1999, American journal of human genetics.

[191]  R. Krüger,et al.  Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype , 1999, Annals of neurology.

[192]  Scott D. Emr,et al.  A Membrane Coat Complex Essential for Endosome-to-Golgi Retrograde Transport in Yeast , 1998, The Journal of cell biology.

[193]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[194]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[195]  E. Tolosa,et al.  Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the α-synuclein gene in early onset patients , 1997, Neuroscience Letters.

[196]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[197]  M. Pericak-Vance,et al.  Genetic Complexity and Parkinson's Disease , 1997 .

[198]  M. Pericak-Vance,et al.  Genetic complexity and Parkinson's disease. Deane Laboratory Parkinson Disease Research Group. , 1997, Science.

[199]  Y. Agid,et al.  Genetic complexity and Parkinson's disease. , 1997, Science.

[200]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[201]  M. Polymeropoulos,et al.  Linkage of the locus for cerebral cavernous hemangiomas to human chromosome 7q in four families of Mexican-American descent , 1997, Neurology.

[202]  T. Taira,et al.  DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. , 1997, Biochemical and biophysical research communications.

[203]  S. Emr,et al.  Alternative pathways for the sorting of soluble vacuolar proteins in yeast: a vps35 null mutant missorts and secretes only a subset of vacuolar hydrolases. , 1992, Molecular biology of the cell.

[204]  M. Yokochi,et al.  Juvenile parkinsonism: a case with first clinical manifestation at the age of six years and with neuropathological findings suggesting a new pathogenesis. , 1991, Clinical neuropathology.

[205]  S. Tsuji,et al.  A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. , 1987, The New England journal of medicine.

[206]  M. Cookson,et al.  The R 1441 C mutation alters the folding properties of the ROC domain of LRRK 2 , 2017 .

[207]  J. Hardy,et al.  Loss of PLA 2 G 6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction , 2015 .

[208]  OF GENETICS. , 2014 .

[209]  J. M. Bravo-San Pedro,et al.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway , 2012, Cellular and Molecular Life Sciences.

[210]  A. Destée,et al.  Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. , 2009, Archives of neurology.

[211]  S. Lindquist,et al.  The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[212]  Á. Carracedo,et al.  Complement factor H. , 2007, Ophthalmology.

[213]  C. Ki,et al.  The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease. , 2007, Clinical genetics.

[214]  A. Singleton,et al.  Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. , 2006, Annals of neurology.

[215]  P. Kolatkar,et al.  The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence , 2006, Human Genetics.

[216]  G. Petsko,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. , 2006, Journal of molecular biology.

[217]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[218]  A Dürr,et al.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.

[219]  R. Edwards,et al.  Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[220]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[221]  G. Halliday,et al.  Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. , 2001, Annals of neurology.

[222]  J. Haines,et al.  The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. , 1999, Neurogenetics.

[223]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[224]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[225]  高橋 均,et al.  Familial juvenile parkinsonism: clinical and pathologic study in afamily , 1993 .

[226]  Nicholas W Wood,et al.  The Parkinson ’ s disease – linked proteins Fbxo 7 and Parkin interact to mediate mitophagy , 2022 .